Recognitions, Board Meetings, Public Offerings, Prequalification Reports, and Distribution Agreements - Research Reports on CME Group, Itau Unibanco, Humana, BD and Zimmer

NEW YORK, September 30, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding CME Group Inc. (NASDAQ: CME), Itau Unibanco Holding S.A. (NYSE: ITUB), Humana Inc. (NYSE: HUM), Becton, Dickinson and Company (NYSE: BDX) and Zimmer Holdings, Inc. (NYSE: ZMH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6846-100free.

--
CME Group Inc. Research Reports
On September 25, 2014, CME Group Inc. (CME Group) announced that it has been named 'International Exchange of the Year for Asia' by Futures & Options World (FOW) at the 3rd FOW Awards for Asia 2014, for the third consecutive year. Commenting on the recognition, Phupinder Gill, CME Group CEO stated, "This award recognizes our commitment to continuously develop products and services offerings in response to the needs of our customers in the region. It also reflects the broadening of our alliances with key strategic partners as our efforts to expand outside of the US continue to take root." The full research reports on CME Group are available to download free of charge at:

http://www.analystsreview.com/Sep-30-2014/CME/report.pdf

--
Itau Unibanco Holding S.A. Research Reports
On September 25, 2014, Itau Unibanco Holding S.A. (Itau Unibanco) released the summarized minutes of the meeting of its board of directors held on the day of the release at 2:00 p.m. in Sao Paulo, Brazil. At the meeting, the Directors decided to amend the wording of 'the Disclosure of Relevant Information and Trading of Itaú Unibanco Securities Policies,' as proposed by the Disclosure and Trading and the Appointment and Governance Committees; and the Transaction with Related Parties Policy. The complete wording of these policies is available in a document archived on the Company's website under Investor Relations section. The full research reports on Itau Unibanco are available to download free of charge at:

http://www.analystsreview.com/Sep-30-2014/ITUB/report.pdf

--
Humana Inc. Research Reports
On September 19, 2014, Humana Inc. (Humana) announced that it has completed its public offering of $1.75 billion in senior notes. Humana informed that these senior notes include $400 million of 2.625% senior notes due October 1, 2019 at 99.995% of the principal amount, $600 million of 3.850% senior notes due October 1, 2024 at 99.867% of the principal amount, and $750 million of 4.950% senior notes due October 1, 2044 at 99.518% of the principal amount ("Senior Notes Offerings"). Excluding underwriters' discounts and estimated offering expenses, the Company expects net proceeds of c.$1.73 billion from the offering. The Company plans to use these proceeds to refinance its 6.45% senior notes maturing in June 2016, to repurchase shares of its common stock pursuant to its existing share repurchase authorization or future authorizations, with the intent to repurchase $1 billion of Humana outstanding shares by no later than June 30, 2015, and for general corporate purposes. The full research reports on Humana are available to download free of charge at:

http://www.analystsreview.com/Sep-30-2014/HUM/report.pdf

--
Becton, Dickinson and Company Research Reports
On September 23, 2014, Becton, Dickinson and Company's (BD) business segment BD Biosciences announced that World Health Organization (WHO) has issued a report prequalifying the BD FACSPresto™ Near-Patient CD4 Counter system for the enumeration of CD4 count to determine eligibility for initiation of Antiretroviral Therapy (ART), staging of the disease and monitoring of HIV-infected patients in middle- and low-volume testing laboratories. According to the Company, WHO's prequalification is required before a product can be included on the WHO's prequalified list and international agencies such as the Global Fund and United Nations can procure systems. BD informed that CD4 testing enables HIV/AIDS patients to access treatment and monitoring, which reduces the probability of transmitting the infection to others and provides a plan for improved long-term care. Claude Dartiguelongue, Worldwide President, BD Biosciences, commented, "We are very pleased that the BD FACSPresto system has received this prequalification and thankful to the WHO for delivering the prequalification so swiftly using the new streamlined process for prequalification of in vitro diagnostics." The full research reports on BD are available to download free of charge at:

http://www.analystsreview.com/Sep-30-2014/BDX/report.pdf

--
Zimmer Holdings, Inc. Research Reports
On September 18, 2014, PRNewswire reported that Zimmer Holdings, Inc. (Zimmer) and MiMedx Group, Inc. (MiMedx) have entered into a distribution agreement, under which MiMedx will provide its dehydrated human amnion/chorion membrane ("dHACM") allograft products to Zimmer to be marketed non-exclusively on a private label basis. According to the news report, Zimmer will market and sell the private-labeled allografts to its customers and end-users throughout the U.S. Commenting on the agreement, Parker H. Petit, MiMedx Chairman and CEO, stated, "We are very pleased about the opportunity to partner with Zimmer. This agreement will facilitate a sizable expansion of the physicians and patients that will now have access to our dHACM allografts. The breadth of the applications included in the agreement and the large base of physicians, hospitals and other medical facilities served by Zimmer will enhance the presence of our allografts in the musculoskeletal sector of the market." The full research reports on Zimmer are available to download free of charge at:

http://www.analystsreview.com/Sep-30-2014/ZMH/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review